Workpackages

WP 4

WP4 studies ways and areas of cooperation in drug research for children. The assumption is that drug R&D requires and benefits from cooperation of the public and the private sector (see WHO report for background reports and analysis).
To provide an overview of existing models for cooperation between public and private funding agents in medicines for children research and identify opportunities for future collaboration

Workpackages team
Workpackage leader: France, INSERM
dr. Florence Emmanuel

Work package team members
The Netherlands, ZonMw
Sweden, SRC

Deliverables
Workpackage 4 Final Report

Workpackage 4 Annexes to final report

D 4.1 Analysis of existing public private research cooperation in medicines for children research

D 4.2 Identification of opportunities and barriers for public-private collaboration